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Objectives The goal of this paper was to determine whether assessment of left ventricular ejection fraction (LVEF) en-
hances prediction of new-onset heart failure (HF) and cardiovascular mortality over and above N-terminal pro–B-
type natriuretic peptide (NT-proBNP) level in older adults.
Background Elevated NT-proBNP levels are common in older adults and are associated with increased risk of HF.
Methods NT-proBNP and LVEF were measured in 4,137 older adults free of HF. Repeat measures of NT-proBNP were per-
formed 2 to 3 years later and echocardiography was repeated 5 years later (n  2,375), with a median
follow-up of 10.7 years. The addition of an abnormal (55%) LVEF (n  317 [7.7%]) to initially elevated or rising
NT-proBNP levels was evaluated to determine risk of HF or cardiovascular mortality. Changes in NT-proBNP lev-
els were also assessed for estimating the risk of conversion from a normal to abnormal LVEF.
Results For participants with a low baseline NT-proBNP level (190 pg/ml; n  2,918), addition of an abnormal LVEF
did not improve the estimation of risk of HF and identified a moderate increase in adjusted risk for cardiovascu-
lar mortality (hazard ratio: 1.69 [95% confidence interval: 1.22 to 2.31]). Among those whose NT-proBNP subse-
quently increased 25% to 190 pg/ml, an abnormal LVEF was likewise associated with an increased risk of
cardiovascular mortality but not HF. Participants with an initially high NT-proBNP level (190 pg/ml) were at
greater risk overall for both outcomes, and those with an abnormal LVEF were at the highest risk. However, an
abnormal LVEF did not improve model classification or risk stratification for either endpoint when added to de-
mographic factors and change in NT-proBNP. An initially elevated NT-proBNP or rising level was associated with
an increased risk of developing an abnormal LVEF.
Conclusions Assessment of LVEF in HF-free older adults based on NT-proBNP levels should be considered on an individual
basis, as such assessments do not routinely improve prognostication. (J Am Coll Cardiol 2011;58:1497–506)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.042Detection of depressed left ventricular function may im-
prove prevention and treatment of progression to symptom-
atic heart failure (1). In adults 50 years of age, the
presence of even a mildly abnormal left ventricular ejection
fraction (LVEF) (i.e., 55%) is associated with an approx-
imately 3-fold increased risk of developing heart failure and
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deaths occur in older adults (5).
However, with a relatively low
prevalence (8%) of an abnor-
mal LVEF even in those age
65 years, it is difficult to advo-
cate a routine imaging strategy in
this population (3,6). Elevated
natriuretic peptide levels are as-
sociated with depressed LVEF in
the general population including
older adults (7,8). Elevated
N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) levels
are also associated with an in-
creased risk of new-onset heart failure in general population
studies (9,10). Currently, neither assessment of natriuretic
peptides nor LVEF is recommended for general population
screening (11). However, a combination of both measures
would potentially refine risk stratification to identify sub-
jects who could benefit from therapies to reduce the risk of
progression to heart failure (12). Following recommenda-
tions from recent guidelines for biomarker assessment of
risk, we sought to determine the additional prognostic
impact of likely downstream testing with echocardiography
Abbreviations
and Acronyms
AUC  area under the
curve
CI  confidence interval
ECG  electrocardiogram
LVEF  left ventricular
ejection fraction
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
Figure 1 Flow Chart of CHS Participants Included in the Study
Flow chart of the CHS (Cardiovascular Health Study) participants with blood samples a
raphy performed at baseline and again during follow-up. *Minority cohort only (2-year i
ventricular ejection fraction.based on NT-proBNP results in this population (13).
Second, to establish if NT-proBNP levels are a biochemical
precursor to left ventricular systolic dysfunction in older
adults, we investigated whether an elevated or rising NT-
proBNP level identifies individuals at risk of progression
from a normal to an abnormal LVEF based on sequential
echocardiography.
Methods
Study population. The CHS (Cardiovascular Health
Study) is a multicenter, prospective observational cohort study of
cardiovascular disease in independently living older adults
(age 65 years) recruited from 4 communities. The study
population consists of the original cohort recruited in 1989
to 1990 and those enrolled in 1992 to 1993 when the study
was expanded to include more African Americans. A
detailed description of the study methods has been pub-
lished previously (14).
Of the 5,888 CHS participants, subjects were included if
they had no prevalent heart failure, interpretable echocar-
diograms, and sufficient serum for NT-proBNP measure-
ment. Ultimately, 4,188 (71.1%) participants were included
in this analysis (Fig. 1). Participants with sufficient sera
volumes and an initial LVEF assessment were modestly
ysis
le for N-terminal pro–B-type natriuretic peptide (NT-proBNP) testing and echocardiog-
between enrollment and echocardiography). HF  heart failure; LVEF  leftAnal
vailab
nterval
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American and diabetic than those without sufficient sera
and/or initial ejection fraction measurement (Online Table 1),
but other factors did not differ.
The institutional review boards of the University of
Washington and the participating centers approved the
CHS. The institutional review board of the University of
Maryland, Baltimore, approved the current analysis.
Echocardiography. The design for the echocardiographic
evaluation of CHS participants has been described previ-
ously (15). In summary, 2-dimensional echocardiography
was performed in 1989 to 1990 and again in 1994 to 1995.
For the original cohort, this corresponded to the baseline
visit and 5 years later. For the second cohort, this resulted in
a single echocardiogram 2 years after the baseline visit.
Global left ventricular systolic function was qualitatively
assessed from the 2-dimensional echocardiogram as normal
(LVEF 5%), borderline (LVEF 45% to 55%), or
subnormal (LVEF 45%) ejection fraction. LVEF was
qualitatively interpreted in 99% of the original CHS cohort,
with inter-reader agreement of 94% and intrareader agree-
ment of 98% of paired studies (16). For this analysis,
subjects with a borderline or subnormal LVEF were
grouped together and classified as having an “abnormal”
LVEF. In addition, we report measures of Doppler mitral
diastolic inflow peak E (early) and peak A (atrial) velocities
and left atrial size measured by linear dimensions based on
2-dimensional directed M-mode imaging (17).
Assay methods. NT-proBNP was measured in serum col-
lected at baseline in the main CHS cohort (1989 to 1990)
and the second cohort (1992 to 1993). A second measure of
NT-proBNP was performed on sera collected 3 years later
for the main cohort (1992 to 1993) and 2 years later for the
second cohort (1994 to 1995).
All samples were stored at –70° to –80° C and were
thawed before testing (maximum of 3 freeze–thaw cycles).
NT-proBNP was measured using electrochemilumines-
cence immunoassay on the Elecsys 2010 system (Roche
Diagnostics, Indianapolis, Indiana). The coefficient of vari-
ation for the NT-proBNP assay was 2% to 5% during the
testing period, and the analytical measurement range for
NT-proBNP was 5 to 35,000 pg/ml. Baseline NT-proBNP
levels 190 pg/ml (the 70th percentile for the study
population) were considered elevated on the basis of previ-
ously identified cutoff values best corresponding with in-
creased risk of heart failure in this population (10).
Primary outcomes. Outcomes were incident heart failure
and cardiovascular mortality. Incident heart failure events
were ascertained through review of medical records, by
participant interview at annual study visits, and semi-annual
phone calls. An expert adjudication panel determined po-
tential heart failure events and cause of mortality (18).
Cardiovascular mortality was defined as mortality related to
atherosclerotic heart disease, mortality after cerebrovascular
disease, or mortality from other atherosclerotic and cardio-
vascular diseases as described in detail previously (18).Clinical history and the electrocardiogram. Clinical
characteristics and cardiovascular risk factors were ob-
tained from the initial CHS study visit for each cohort
(for the analysis of baseline NT-proBNP and outcomes)
or at the study visit of the follow-up NT-proBNP (for the
analysis of change in NT-proBNP and outcomes). The
methods for assessing cardiovascular risk factors have
been described previously (19).
Coronary heart disease was defined as a history of angina,
myocardial infarction, coronary angioplasty, or coronary
artery bypass surgery. An electrocardiogram (ECG) was
performed annually; left ventricular mass was estimated
from the ECG, and major ECG abnormalities, including
atrial fibrillation and left ventricular hypertrophy, were
defined according to previously described methods (20,21).
Statistical methods. Characteristics according to baseline
NT-proBNP and left ventricular functional status were
compared using chi-square tests or 1-way analysis of vari-
ance as appropriate. Cumulative incidence of heart failure
and cardiovascular mortality were estimated using the
Kaplan-Meier method. Multivariate analyses were per-
formed using Cox proportional hazards models for new-
onset heart failure and cardiovascular mortality outcomes,
adjusting for demographic characteristics (age, sex, and
race), cardiovascular disease history, cardiovascular risk fac-
tors (systolic blood pressure, diabetes, cholesterol, creati-
nine, and body mass index), use of antihypertensive medi-
cations, and major ECG abnormalities. Elevated NT-proBNP
was defined using a previously validated cutoff value of
190 pg/ml (10).
Change in NT-proBNP was considered as a categorical
predictor among those with an initial low NT-proBNP level
of 190 pg/ml. Risk of heart failure and cardiovascular
mortality were examined associated with: 1) a stable or
decrease in NT-proBNP level (i.e., no increase 25%); and
2) an increase of at least 25% to a level 190 pg/ml. The
25% threshold for change was based on the reported
intraindividual variability in NT-proBNP levels in patients
with stable heart failure (22). We then evaluated whether
baseline echocardiographic information about LVEF (55%
vs. 55%) added to the predictive value of increases in
NT-proBNP. Last, we evaluated the incremental value of
LVEF as a semi-quantitative variable (45%, 45% to 54%
and55%) and NT-proBNP as a continuous variable (after
log-transformation) for both outcomes. The time-
dependent C-statistic was used to examine the added
predictive value of the LVEF assessment to: 1) a demo-
graphic model with and without baseline NT-proBNP
levels; and 2) the combination of baseline and of follow-up
NT-proBNP levels for incident heart failure and cardiovas-
cular mortality. The improvement in risk classification by
the addition of LVEF measurements to NT-proBNP levels
in demographic adjusted models was examined using the net
reclassification improvement (NRI), which represents the
net percentage of subjects correctly reclassified to risk
categories (23). We categorized individuals according to
e
g
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cular mortality of 10%, 10% to 20%, or 20%. An
xploratory analysis was also performed using echocardio-
raphic measures of diastolic function, including Doppler
itral E/A ratio (categorized as0.7, 0.8 to 1.5, and1.5)
and left atrial dimension added to LVEF, NT-proBNP, or
both.
Association between changes in NT-proBNP and subse-
quent new-onset left ventricular dysfunction were evaluated
using chi-square tests. Statistical analyses were performed
with Stata version 10 (Stata Corp., College Station, Texas)
and SPSS version 17.0 (SPSS Inc., Chicago, Illinois), and
time-dependent C-statistics were generated using R version
2.7.0. (24).
Results
Participant characteristics. Of the 4,137 participants
without prevalent heart failure and a baseline echocar-
Characteristics of Participants as Related to NT-proBNP and LVEFTable 1 Characteristics of Participants as Related to NT-proBN
Variable
Total
(N  4,137)
NT-proBNP <
LVEF >55%
(n  2,783)
Demographics
Age (yrs) 72.7 5.5 71.6 4.8
Female 2,462 (59.3%) 1,689 (60.8%)
Race (African American) 548 (13.2%) 411 (14.8%)
Risk factors
SBP (mm Hg) 136.6 21.4 133.9 19.9
DBP (mm Hg) 70.8 11.1 70.7 10.8
Hypertension 1,823 (44.1%) 1,118 (40.2%)
Diabetes 715 (17.3%) 483 (17.4%)
BMI (kg/m2) 26.6 4.6 26.8 4.6
Current smoker 453 (11.0%) 311 (11.2%)
Cardiovascular history
CHD at baseline 727 (17.6%) 345 (12.4%)
ECG abnormalities
LVH on ECG 172 (4.3%) 64 (2.4%)
Atrial fibrillation 89 (2.2%) 13 (0.5%)
Laboratory values
NT-proBNP (pg/ml) 110.5 [56.4–218.8] 76.4 [43.3–117.5]
eGFR (ml/min/1.73 m2) 79.0 23.2 81.8 22.3
Cholesterol (mg/dl) 212.3 39.0 214.6 38.3
Medications at baseline visit
ACE inhibitor 258 (6.2%) 169 (6.1%)
Beta-blocker 554 (13.4%) 281 (10.1%)
Diuretic 1,015 (24.6%) 623 (22.4%)
Antihypertensive (any) 1,889 (45.7%) 1,149 (41.3%)
Digoxin 279 (6.8%) 121 (4.4%)
Lipid-lowering drugs 240 (5.8%) 170 (6.1%)
Echocardiography measurements
Left atrial diameter (cm) 3.9 (0.7) 3.8 (0.6)
E/A 0.7 810 (20.1%) 499 (18.3%)
E/A 0.7–1.5 3,002 (74.5%) 2,147 (78.9%)
E/A 1.5 218 (5.4%) 76 (2.8%)
Values are mean  SD, n (%), or median [interquartile range]. *p value not calculated (NA) becau
ACEangiotensin-converting enzyme; BMIbodymass index; CHD cardiovascular heart disease; DBPdias
GFR estimated glomerular filtration rate; LVEF left ventricular ejection fraction; LVH left ventricular hypertrdiogram, 107 (2.6%) had subnormal LVEF (45%) and
210 (5.1%) had a borderline reduced LVEF (45% to
54%). The area under the curve (AUC) for NT-proBNP
to diagnose a subnormal LVEF (45%) was 0.85, and for
any abnormal LVEF (55%), the AUC was 0.69. High-
risk NT-proBNP levels (190 pg/ml) were observed in
29.5% (n  1,219). Table 1 displays demographic,
clinical, and echocardiographic diastolic information
based on the presence of a high or low NT-proBNP
value, further subdivided by the presence of a normal
versus abnormal LVEF. The median age of the partici-
pants was 71 years (range 65 to 100 years). NT-proBNP
status (high vs. low) differentiated patients with a higher
prevalence of risk factors, ECG abnormalities, history of
coronary heart disease, cardiovascular medication use,
increased left atrial size, and diastolic abnormalities. An
abnormal LVEF was further associated with male sex,
diabetes, coronary heart disease, ECG abnormalities,
d LVEF
g/ml NT-proBNP >190 pg/ml
p Value
LVEF <55%
(n  135)
LVEF >55%
(n  1,037)
LVEF <55%
(n  182)
71.7 4.8 75.2 6.2 75.5 6.0 0.001
44 (32.1%) 686 (64.4%) 63 (34.6%) 0.001
19 (14.1%) 129 (12.1%) 20 (10.9%) 0.037
132.0 17.1 143.6 23.5 141.5 24.0 0.001
71.07 11.2 70.9 11.7 71.9 13.2 0.403
61 (45.2%) 551 (53.2%) 93 (51.1%) 0.001
34 (25.2%) 155 (14.9%) 43 (23.6%) 0.002
27.9 4.5 25.9 4.7 26.5 4.34 0.001
14 (10.4%) 113 (10.9%) 15 (8.2%) 0.668
40 (29.6%) 243 (23.4%) 99 (54.4%) 0.001
5 (3.9%) 82 (8.3%) 21 (12.8%) 0.001
1 (0.7%) 59 (5.9%) 16 (9.8%) 0.001
.8 [43.4–124.5] 314.1 [236.0–522.5] 530.6 [299.8–1208.0] NA*
79.7 23.1 73.1 24.2 68.7 23.4 0.001
211.5 40.2 208.2 39.7 201.1 42.1 0.001
9 (6.7%) 64 (6.2%) 18 (8.8%) 0.516
20 (14.9%) 216 (20.8%) 37 (20.4%) 0.001
36 (26.9%) 305 (29.4%) 51 (28.2%) 0.001
73 (54.5%) 558 (53.8%) 109 (60.29%) 0.001
5 (3.7%) 119 (11.5%) 34 (18.8%) 0.001
7 (5.2%) 51 (4.9%) 12 (6.6%) 0.515
4.0 (0.7) 4.0 (0.7) 4.3 (0.8) 0.001
36 (27.3%) 209 (20.8%) 66 (38.4%) 0.001
95 (72.0%) 685 (68.2%) 75 (43.6%)
1 (0.8%) 110 (11.0%) 31 (18.0%)
roBNP was used to create the grouping variable.P an
190 p
88
se NT-p
tolic blood pressure; E/A ratio of peakmitral diastolic E- andA-wave velocities; ECG electrocardiogram;
ophy; NT-proBNP N-terminal pro–B-type natriuretic peptide; SBP systolic blood pressure.
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and diastolic abnormalities.
Outcomes based on NT-proBNP levels and LVEF. The
median follow-up was 10.7 years (range 0.1 to 14.1 years)
from the time of the baseline measure. There were 1,112
participants who developed heart failure, and 893 who died
of cardiovascular causes. The unadjusted hazard ratios for
heart failure were 2.95 (95% confidence interval [CI]: 2.61
to 3.32) and 2.42 (95% CI: 2.03 to 2.90) for a baseline
NT-proBNP level 190 pg/ml and LVEF 55%, respec-
tively. Survival functions for heart failure and cardiovascular
mortality based on the combination of baseline NT-
proBNP level and LVEF assessment are shown in the
Kaplan-Meier plots in Figures 2A and 2B. Differentiation
of risk occurred within the first year and continued through-
Figure 2 Survival Plots for Outcomes Using
Baseline LVEF and NT-proBNP Level
Unadjusted Kaplan-Meier plots for (A) time to new-onset HF diagnosis and (B)
time to cardiovascular mortality based on the combination of a baseline low
(190 pg/ml) or high (190 pg/ml) NT-proBNP and normal or abnormal LVEF.
p  0.001 for comparison of survival curves for both HF and cardiovascular
mortality. Abbreviations as in Figure 1.out follow-up. As shown in Table 2 in an unadjusted
analysis, the increased risks of heart failure or cardiovascular
mortality were of significant magnitude among participants
with a low NT-proBNP and an abnormal LVEF (a 1.7- to
2.3-fold increased risk) compared with those with a normal
LVEF. For participants with high baseline NT-proBNP,
risks of heart failure and cardiovascular mortality were
higher, and this finding was further stratified by LVEF
assessment.
After adjustment for clinical risk factors, body mass
index, ECG abnormalities, and cardiovascular medications
in those with low or high NT-proBNP levels, the increased
risk associated with the presence of an abnormal LVEF was
markedly attenuated but remained significant for both
outcomes among those with an initially high NT-proBNP
level and for cardiovascular mortality among those with an
initially low NT-proBNP level. An abnormal LVEF was no
longer associated with risk of heart failure among those with
an initially low NT-proBNP (Table 2). In contrast, in a
statistical model using NT-proBNP as a continuous variable
and LVEF as a semi-quantitative variable, LVEF continued
to predict both outcomes after multivariate adjustment
(Online Table 2). In a separate sex-based analysis, no
differences in the combined effects of LVEF and NT-
proBNP were observed between men and women (Online
Table 3).
To complement the Cox regression analysis, the
C-statistic and NRI were used to evaluate the incremental
predictive value of LVEF assessment to NT-proBNP mea-
surement for each outcome (Table 3). For both heart failure
and cardiovascular death, the addition of LVEF improved
prediction compared with demographic characteristics alone
and resulted in a modest reclassification of risk. In contrast,
the addition of LVEF assessment to demographic informa-
tion and the NT-proBNP level resulted in minimal, but
statistically significant, improvement in the C-statistic for
only the outcome of heart failure and no reclassification of
risk for either outcome by the NRI statistic. When restrict-
ing the analyses to individuals with an initially elevated
NT-proBNP, LVEF assessment did not reclassify risk of
heart failure or cardiovascular mortality beyond demo-
graphic information and NT-proBNP level (cardiovascular
mortality: NRI, 0.006, p  0.7; heart failure: NRI, 0.008;
p  0.2). Adding echocardiographic measures of diastolic
function to LVEF resulted in a significant increase in the
C-statistic and reclassification by NRI. However, the addi-
tion of NT-proBNP still significantly increased the
C-statistic and improved reclassification even after account-
ing for both LVEF and diastolic measures along with
demographic characteristics.
As part of a secondary analysis, we also determined the
number of participants who would need to undergo echo-
cardiography to detect either one subnormal (45%) or
abnormal (55%) LVEF based on an initially high NT-
proBNP (Online Table 4).
T
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assessment. Echocardiography was available for 2,375 par-
ticipants with repeat NT-proBNP levels who had not
developed heart failure in the interim between measures
(Fig. 1). LVEF55% (n 202 [8.5%]) was associated with
increased risk of subsequent heart failure (n  505 events;
hazard ratio: 2.38 [95% CI: 1.80 to 3.13]) and cardiovas-
cular mortality (n 390 events; hazard ratio: 2.93 [95% CI:
2.18 to 3.98]).
We then investigated whether LVEF assessments would
add to the risk of both outcomes over and above repeated
NT-proBNP assessments in participants with initially low
NT-proBNP levels (190 pg/ml, n  1,840). Participants
were subdivided by comparing those whose NT-proBNP
levels had increased25% to190 pg/ml versus those with
stable or decreased NT-proBNP levels.
Among participants with initially low NT-proBNP lev-
els, 361 (19.6%) had increased at follow-up. For these
participants, the risk of heart failure was highest among
those with an abnormal LVEF, with intermediate risk being
present in participants with only one characteristic (i.e.,
either an increase in NT-proBNP or an abnormal LVEF)
(Fig. 3A). For cardiovascular mortality, a persistently low
NT-proBNP level indicated a low risk, irrespective of
LVEF, whereas LVEF assessment further differentiated the
risk of cardiovascular death in individuals with an increase
Cox Regression Analysis for Endpoints Based on the Initial NT-proBTable 2 Cox Regression Analysis for Endpoints Based on the In
Measurement Patients
Heart
No. of
Events Unadjusted
Low NT-proBNP/normal LVEF 2,783 (67.3%) 575 1.00
Low NT-proBNP/LVEF 55% 135 (3.3%) 44 1.75 (1.29–2.3
High NT-proBNP/normal LVEF 1,037 (25.1%) 400 2.75 (2.42–3.1
High NT-proBNP/LVEF 55% 162 (4.4%) 93 5.73 (4.60–7.1
Values are n (%) or HR (95% CI). *Hazard ratios adjusted for demographic characteristics (age, se
mass index, and creatinine), use of antihypertensive medications, andmajor ECG abnormalities. †In
for new-onset heart failure comparing participants with a normal LVEF versus LVEF 55%. ‡In pa
for cardiovascular mortality comparing participants with a normal LVEF versus LVEF 55%.
Abbreviations as in Table 1.
Time-Dependent C-Statistic and NRI for Progressively More CompleOutcomes Usi g LVEF and a Single Measure of NT-proBNPTable 3 Time-Dependent C-Statistic and NRI for Prog ssively MOutcomes Using LVEF and a Single Measure of NT-pro
Model
Compared With
Model No. A
1. Demographics 0
2. Demographics  LVEF 1 0
3. Demographics  LVEF  diastolic measurements* 2 0
4. Demographics  LVEF  diastolic measurements*
 baseline NT-proBNP
3 0
5. Demographics  NT-proBNP 1 0
6. Demographics  NT-proBNP  LVEF 5 0
7. Demographics  NT-proBNP  LVEF  diastolic
measures*
6 0*Diastolic measures: mitral inflow velocity E/A ratio (0.7, 0.7–1.5, and 1.5), left atrial diameter.
AUC  area under the curve; NRI  net reclassification improvement; other abbreviations as in Tablein NT-proBNP level (Fig. 3B). By Cox regression analysis,
after adjustment for covariates, LVEF only differentiated
risk in the cohort of participants with a rising NT-proBNP
level, and only for cardiovascular death (Table 4).
The C-statistic and NRI analysis confirmed the findings
from the adjusted Cox regression models. The addition of
LVEF assessment to demographic information and serial
NT-proBNP measurements neither significantly increased
the AUC for the C-statistic nor reclassified the risk of
having either outcome using the NRI statistic (Table 5).
Similar to models with a single measure of NT-proBNP,
echocardiographic diastolic parameters provided additional
prognostic and reclassification information to LVEF and
serial NT-proBNP concentrations.
As part of a secondary analysis based on change in
NT-proBNP level, we determined the number of partici-
pants who would need to undergo echocardiography to
detect either one subnormal (45%) or abnormal (55%)
LVEF based on an initial NT-proBNP level of190 pg/ml
that increased 25% to 190 pg/ml at follow-up (Online
able 4).
redicting a decline in LVEF based on serial NT-
roBNP levels. Participants in the main cohort with an
T-proBNP level 190 pg/ml and a normal LVEF had
epeat echocardiograms 2 years after their second measure of
T-proBNP level (n  1,486). An abnormal LVEF devel-
nd LVEF MeasurementsNT-proBNP and LVEF Measurements
Cardiovascular Mortality
Adjusted*
No. of
Events Unadjusted Adjusted*
1.00 424 1.00 1.00
1.26 (0.92–1.73) 43 2.34 (1.59–3.45) 1.68 (1.22–2.31)
2.05 (1.78–2.36) 327 2.67 (2.22–3.22) 1.92 (1.63–2.26)
2.67 (2.07–3.44)† 99 5.45 (3.94–7.54) 2.95 (2.30–3.79)‡
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pants with a high NT-proBNP level, there was a significant difference (p 0.03) in the hazard ratios
ts with a high NT-proBNP level, there was a significant difference (p  0.001) in the hazard ratios
dictive Models ofComplex Predictive Models of
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September 27, 2011:1497–506 LVEF Assessment With NT-proBNP to Assess Riskoped in 95 patients (6.4%). Participants with an increase in
NT-proBNP level were significantly more likely to have
Figure 3 Survival Plots for Outcomes Using
Follow-Up LVEF and Change in NT-proBNP Level
Unadjusted Kaplan-Meier plots for participants with baseline NT-proBNP 190 pg/ml
(A) time to new-onset HF diagnosis and (B) time to cardiovascular mortality based on
the increase or absence of an increase in NT-proBNP level at follow-up and a normal or
abnormal LVEF at echocardiography at follow-up. p 0.001 for comparison of survival
curves for both HF and cardiovascular mortality. Abbreviations as in Figure 1.
Risk of New-Onset Heart Failure and Cardiovascular Mortality BaseChange in NT-proBNP in Patients With Low NT-proBNP a BaselineTable 4 Risk of New-Ons t Hear F ilure and Cardi v scular MChange in NT-proBNP in Patients With Low NT-proBNP
Model No. (%) of Patients Unadju
Stable† NT-proBNP/normal LVEF 1,399 (58.9%) 1.00
Stable† NT-proBNP/LVEF 55% 80 (3.4%) 1.94 (1.17
Increased NT-proBNP/normal LVEF 319 (13.3%) 2.77 (2.21
Increased NT-proBNP/LVEF 55% 42 (1.8%) 5.90 (2.91
Values are n (%) or HR (95% CI). *Adjusted for demographic characteristics (age, sex, and race), CH
mass index), use of antihypertensive medications, major ECG abnormalities, and baseline NT-proB
is 0.05 for comparison between a normal and abnormal baseline LVEF among participants with an NT
Abbreviations as in Table 1.subsequent decline in their LVEF compared with partici-
pants with a stable low NT-proBNP level. Those who
started with a high NT-proBNP and a normal LVEF
(n  426) had a similar proportion who developed an
bnormal LVEF as those with an initially normal but rising
T-proBNP (Fig. 4).
iscussion
he results from this study demonstrate that, in ambulatory
lder adults without heart failure, the addition of LVEF
ssessment to either a single NT-proBNP assessment or
equential measures adds little to risk assessment for new-
nset heart failure or cardiovascular mortality. Furthermore,
n contrast to NT-proBNP levels, LVEF alone only mod-
stly reclassifies risk when considering just demographic
haracteristics. Confirming the limited utility of a natri-
retic peptide level to “screen” for subnormal (i.e., 45%)
VEF, 14 participants with a high baseline NT-proBNP
evel and 34 participants with rising NT-proBNP levels
ould need to be screened to detect one subnormal LVEF.
espite limited accuracy to detect a subnormal LVEF, a
igh baseline or an increasing NT-proBNP level identified
ndividuals at greatest risk of developing a new abnormal
VEF on follow-up echocardiography. This latter finding is
otentially intriguing because many CHS participants with
nitially normal LVEF who develop symptoms of heart
ailure are found to have an abnormal LVEF at the time of
resentation (25).
In CHS and other community population studies, an
bnormal LVEF is an independent predictor of both new
eart failure hospitalizations and cardiovascular mortality
2–4,26). Yet in this analysis, once adjusted for comorbidi-
ies, LVEF assessment added little additional predictive
enefit beyond the measurement of NT-proBNP. There are
everal potential reasons for this new finding. First, an
bnormal LVEF is a relatively infrequent finding in
ommunity-dwelling older adults (8%) compared with an
levated NT-proBNP level (approximately 30%) (3,6,10).
he low prevalence accounts in part for the weak influence
f LVEF in reclassifying risk of heart failure or cardiovas-
ular death (Tables 3 and 5). The lack of specificity of
atriuretic peptides for increased left ventricular volumes or
Follow-Up LVEF and1,840)ty Based on Follow-Up LVEF and
aseline (N  1,840)
eart Failure Cardiovascular Mortality
Adjusted* Unadjusted Adjusted*
1.00 1.00 1.00
1.34 (0.80–2.24) 1.71 (0.90–3.22) 1.09 (0.57–2.11)
2.15 (1.66–2.80) 2.24 (1.78–3.12) 1.83 (1.33–2.52)
) 3.19 (1.46–6.99) 8.89 (4.68–16.89) 4.73 (2.37–9.45)‡
ry, cardiovascular risk factors (systolic blood pressure, diabetes, cholesterol, creatinine, and body
el. †Stable includes participants with stable or decreased NT-proBNP levels at follow-up. ‡p valued on(N ortali
at B
H
sted
–3.23)
–3.48)
–11.98
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NP lev-proBNP that increased between baseline and follow-up.
er.
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LVEF Assessment With NT-proBNP to Assess Risk September 27, 2011:1497–506pressure in asymptomatic subjects can explain the false
positive results when using NT-proBNP as a screening tool
for an abnormal LVEF in the general population (27–29).
Assessment of LVEF to refine prognostication in
community-dwelling older adults on the basis of an elevated
natriuretic peptide level should be approached cautiously.
Despite a previous study suggesting that natriuretic peptide
measurement could be cost-effective in select populations to
screen for abnormal LVEF, recent guidelines do not rec-
ommend measuring either natriuretic peptides or LVEF as
part of a screening strategy (11,12). It may be tempting to
consider combining natriuretic peptide levels and LVEF to
Time-Dependent C-Statistic AUC and NRI for Progressively More CoOutcomes Usi g LVEF, Diastolic Measures, and Repeat d easureTable 5 Time-Dependen C-St tistic AUC and NRI for Prog ssiOutcomes Using LVEF, Diastolic Measures, and Repea
Model
Compared With
Model No.
1. Demographics
2. Demographics  LVEF 1
3. Demographics  LVEF  diastolic measures* 2
4. Demographics  LVEF  diastolic measures*
 baseline and second NT-proBNP
3
5. Demographics  baseline and second NT-proBNP 1
6. Demographics  baseline and second NT-proBNP  LVEF 5
7. Demographics  baseline and second NT-proBNP  LVEF 
diastolic measures*
6
*Diastolic measures: mitral inflow velocity E/A ratio (0.7, 0.7–1.5, and 1.5), left atrial diamet
Abbreviations as in Tables 1 and 3.
Figure 4 Participants Whose LVEF Changed From Normal to
Abnormal as Predicted by NT-proBNP Levels
Participants whose LVEF changed from normal to abnormal (LVEF 55%) from
baseline to follow-up echocardiogram as predicted by serial NT-proBNP levels or an
initial high level. Low indicates NT-proBNP 190 pg/ml. High indicates an initial
NT-proBNP level 190 pg/ml or an increase 25% to 190 pg/ml. Abbreviations
as in Figure 1.identify those at greatest risk, and by unadjusted analysis,
this seems to be present. With introduction and dispersion
of inexpensive handheld ultrasound imaging devices, rapid
and less-expensive assessment of LVEF will become prev-
alent (30). However, once comorbidities are considered, the
additional prognostication of LVEF to an NT-proBNP
level is markedly attenuated. Furthermore, the addition of
LVEF provides insignificant information to improve dis-
crimination and reclassify individuals into lower- or high-
risk groups even when considering only participants with
initially high NT-proBNP. Our findings should be con-
trasted to earlier findings in the post-myocardial infarction
setting in which natriuretic peptide levels and LVEF have
prognostic synergism for both heart failure and death (31).
However, reflective of the differences between a post-
myocardial infarction population and screening “at-risk”
community-based subjects, the prevalence of an abnormal
LVEF was approximately 10 times higher in the post-
myocardial infarction setting (31). In older adults without
known heart failure, clinicians will need to individualize
decision making with respect to echocardiography even in
the presence of a high NT-proBNP level indicating an
increased risk of developing heart failure symptoms, while
also considering the importance of knowing diastolic filling
patterns, left atrial size, or other cardiac pathologic condi-
tions in specific cases.
Study limitations. This was a large, well-characterized
cohort of community-dwelling older adults with serial
NT-proBNP levels and echocardiography. However, there
are limitations to the study design. The addition of the
second cohort of African-American older adults provides
for a balanced demographic reflective of older adults in the
United States. For this group, baseline NT-proBNP was
measured 2 years before an echocardiogram. We have
shown that LVEF will change over time but only in a
minority of participants even in the presence of an abnormal
NT-proBNP level.
In CHS, LVEF was not quantified as a percentage.
Interpretation was performed in a semi-quantitative man-
x Predictive Models ofNT-proBNPore Complex Predictive Models of
easures of NT-proBNP
Heart Failure Cardiovascular Mortality
UC p Value NRI p Value AUC p Value NRI p Value
661 0.700
670 0.06 0.022 0.08 0.714 0.015 0.055 0.006
702 0.001 0.079 0.001 0.734 0.004 0.047 0.052
771 0.001 0.152 0.001 0.779 0.001 0.144 0.001
755 0.001 0.212 0.001 0.762 0.001 0.170 0.001
758 0.23 0.000 0.9 0.766 0.22 0.023 0.11
771 0.009 0.034 0.04 0.779 0.003 0.046 0.001mples ofvely M
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September 27, 2011:1497–506 LVEF Assessment With NT-proBNP to Assess Riskibility (16). It is noteworthy that poor outcomes have been
associated with even a borderline LVEF (estimated at 45%
to 55%) (3). Last, this study does not incorporate all
echocardiographic measures of diastolic function, but we do
show that diastolic measures can assist in reclassifying risk
beyond LVEF and NT-proBNP levels. It remains complex
as to how best to integrate diastolic measures into an
individual’s care.
Conclusions
Older adults comprise the majority of new cases of heart
failure, yet most live many years without the diagnosis.
Elevated NT-proBNP levels likely reflect an ongoing
pathologic process that can initially manifest as progression
to an abnormal LVEF before symptoms or as symptoms in
the presence of preserved LVEF. Once adjusting for the
multiple comorbidities often present in ambulatory older
adults, we were unable to demonstrate that an assessment of
LVEF could further stratify prognosis after measurement of
NT-proBNP. In the presence of an elevated NT-proBNP
level in this population, a tailored approach to cardiac
imaging appears most appropriate.
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